Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
Source: Press Release
Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination